Arachnoiditis from experimental myelography with aqueous contrast media

Area of Science:

• Radiology
• Neurology
• Toxicology

Background:

• Postmyelographic arachnoiditis is a potential complication.
• Understanding contrast agent risks is crucial for spinal imaging safety.

Purpose of the Study:

• To evaluate the arachnoiditis-inducing potential of different myelography contrast agents.
• To assess the efficacy of dilution and prophylactic medication in preventing arachnoiditis.

Main Methods:

• Myelography was conducted on 80 monkeys using metrizamide and meglumine iocarmate.
• Various concentrations of contrast media were tested.
• Prophylactic intrathecal methylprednisolone was administered to a subset of animals.
• The presence and severity of arachnoiditis were assessed.

Main Results:

• High concentrations of metrizamide myelography induced arachnoiditis.
• Meglumine iocarmate also caused arachnoiditis, but dilution significantly reduced this risk.
• Prophylactic intrathecal methylprednisolone did not prevent arachnoiditis.
• The presence of blood in cerebrospinal fluid did not influence arachnoiditis severity.

Conclusions:

• Contrast agent concentration is a key factor in metrizamide-induced arachnoiditis.
• Diluting meglumine iocarmate is an effective strategy to mitigate arachnoiditis risk.
• Intrathecal methylprednisolone is not effective for preventing postmyelographic arachnoiditis.